Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 101–200 of 1,000
Metabolic and Immune Crosstalk in Cardiovascular Disease
Mohanta, S. K., Heron, C., Klaus‐Bergmann, A., Horstmann, H., Bråkenhielm, E., Giannarelli, C., Habenicht, A. J. R., Gerhardt, H., & Weber, C. (2025) · Circulation Research · doi:10.1161/circresaha.125.325496 · Cited by 77
Endothelial and vascular smooth muscle dysfunction in hypertension
de Oliveira, M. G., Nadruz, W., & Mónica, F. Z. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115263 · Cited by 68
The Treatment of Heart Failure with Reduced Ejection Fraction
Berliner, D., Hänselmann, A., & Bauersachs, J. K. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0376 · Cited by 78
Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO
de la Fuente‐Alonso, A., Toral, M., Alfayate, Á., Ruiz-Rodríguez, M. J., Bonzón‐Kulichenko, E., Teixidó‐Turà, G., Martínez-Martínez, S., Méndez-Olivares, M. J., López-Maderuelo, D., Gonzalez-Valdes, I. B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22933-3 · Cited by 68
Endothelial Dysfunction in Heart Failure: What Is Its Role?
Drera, A., Rodella, L., Brangi, E., Riccardi, M., & Vizzardi, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092534 · Cited by 74
“…issues, two innovative drug classes, sGC stimulators and sGC activators, have emerged as promising treatments for HF. Notably, the VICTORIA trial [69] evaluated the effectiveness and safety of Vericiguat, an oral sGC stimulator, in patients with reduced left ventricular ejection fraction (LVEF)…”
MethodTomasoni, D., Pagnesi, M., Colombo, G., Chiarito, M., Stolfo, D., Baldetti, L., Lombardi, C., Adamo, M., Maggi, G., Inciardi, R. M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3081 · Cited by 68
Packer, M., & Metra, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1857 · Cited by 61
Carbon Monoxide and Nitric Oxide as Examples of the Youngest Class of Transmitters
Nowaczyk, A., Kowalska, M., Nowaczyk, J., & Grześk, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116029 · Cited by 64
Comparing the Benefit of Novel Therapies Across Clinical Trials
Butler, J., Anstrom, K. J., Armstrong, P. W., & For the VICTORIA Study Group (2020) · Circulation · doi:10.1161/circulationaha.120.047086 · Cited by 58
Self-citationSacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction
Mann, D. L., Greene, S. J., Givertz, M. M., Vader, J. M., Starling, R. C., Ambrosy, A. P., Shah, P. M., McNulty, S. E., Mahr, C., Gupta, D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.05.005 · Cited by 57
Self-citationPonikowski, P. P., Alemayehu, W. G., Oto, A., Bahit, M. C., Noori, E., Patel, M. J., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2285 · Cited by 66
Self-citationFilippatos, G. S., Anker, S. D., Butler, J., Farmakis, D. T., Ferreira, J. P., Gollop, N. D., Brueckmann, M., Iwata, T., Pocock, S., Zannad, F. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2707 · Cited by 58
Self-citationManagement of Worsening Heart Failure With Reduced Ejection Fraction
Greene, S. J., Bauersachs, J. K., Brugts, J. J., Ezekowitz, J. A., Filippatos, G. S., Gustafsson, F., Lam, C. S. P., Lund, L. H., Mentz, R. J., Pieske, B. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.057 · Cited by 62
Self-citation2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
Petraina, A., Nogales, C., Krahn, T., Mucke, H. A., Lüscher, T. F., Fischmeister, R., Kass, D. A., Burnett, J. C. J., Hobbs, A. J., & Schmidt, H. H. H. W. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab240 · Cited by 58
Rosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 72
Zannad, F. M., O’Connor, C. M., Butler, J., McMullan, C. J., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Gates, D. F., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01682-4 · Cited by 66
Self-citationRecurrent Events in Cardiovascular Trials
Gregson, J., Stone, G. W., Bhatt, D. L., Packer, M., Anker, S. D., Zeller, C., Redfors, B., & Pocock, S. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.024 · Cited by 59
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
ZHANG, S.-Y. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.03.002 · Cited by 66
A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction
Miller, R. J. H., Howlett, J. G., & Fine, N. M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.028 · Cited by 57
Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System
Ueda, K., Fukuma, N., Adachi, Y., Numata, G., Tokiwa, H., Toyoda, M., Otani, A., Hashimoto, M., Liu, P., & Takimoto, E. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.738218 · Cited by 61
“The Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) study showed cardiovascular protection by the soluble guanylate cyclase (sGC) stimulator vericiguat (Armstrong et al., 2020).”
BackgroundTriposkiadis, F. K., Xanthopoulos, A. V., Skoularigis, J. S., & Starling, R. C. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10239-5 · Cited by 57
“8 months, significantly lowered the incidence of death from cardiovascular causes or hospitalization for HF [80].”
BackgroundVascular (dys)function in the failing heart
Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 61
“In the landmark VICTORIA trial 211 , vericiguat reduced the risk of HF hospitalization or cardiovascular death in patients with worsening HFrEF, suggesting that a subgroup of patients with HFrEF benefit from stimulation of the sGC pathway.”
Krzesiński, P., Jankowska, E. A., Siebert, J., Galas, A. A., Piotrowicz, K., Stańczyk, A., Siwołowski, P., Gutknecht, P. G., Chrom, P., Murawski, P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2358 · Cited by 59
Self-citationCalamera, G., Moltzau, L. R., Levy, F. O., & Andressen, K. W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042145 · Cited by 63
New drug approvals for 2021: Synthesis and clinical applications
Yuan, S., Wang, D.-S., Liu, H., Zhang, S., Yang, W., Lv, M., Zhou, Y., Zhang, S., Song, J. H., & Liu, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114898 · Cited by 54
Rohde, L. E. P., Zimerman, A., Vaduganathan, M., Claggett, B. L., Packer, M., Desai, A. S., Zile, M. R., Rouleau, J. L., Swedberg, K. B., Lefkowitz, M. P., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4427 · Cited by 61
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment
Youn, J., Kim, D., Cho, J. Y., Cho, D., Park, S. M., Jung, M., Hyun, J., Cho, H., Park, S., Choi, J., et al. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0011 · Cited by 58
Current landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Drug Layering in Heart Failure
Rosano, G. M. C., Allen, L. A., Abdin, A., Lindenfeld, J. M., O’Meara, E., Lam, C. S. P., Lancellotti, P., Savarese, G., Gottlieb, S. S., Teerlink, J. R., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.011 · Cited by 55
Self-citationGreene, S. J., Ezekowitz, J. A., Anstrom, K. J., Demyanenko, V., Givertz, M. M., Piña, I. L., O’Connor, C. M., Koglin, J., Roessig, L., Hernandez, A. F., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.011 · Cited by 49
Self-citationCoats, A. J. S., Abraham, W. T., Zile, M. R., Lindenfeld, J. A., Weaver, F. A., Fudim, M., Bauersachs, J. K., Duval, S., Galle, E. G., & Zannad, F. M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2573 · Cited by 51
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science
Trujillo, M. E., Ayalasomayajula, S. P., Blaustein, R. O., & Gheyas, F. (2023) · Clinical and Translational Science · doi:10.1111/cts.13677 · Cited by 59
“From Armstrong PW et al. 20 Copyright © 2020 Massachusetts Medical Society, with permission from Massachusetts Medical Society .”
BackgroundEzekowitz, J. A., Zheng, Y., Solal, A. C., Melenovský, V., Escobedo, J., Butler, J., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056797 · Cited by 49
Self-citationFinerenone in Patients With a Recent Worsening Heart Failure Event
Desai, A. S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Jhund, P. S., Cunningham, J. W., Borentain, M., Lay‐Flurrie, J., Viswanathan, P., Rohwedder, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.004 · Cited by 62
Self-citationPKG1α Cysteine-42 Redox State Controls mTORC1 Activation in Pathological Cardiac Hypertrophy
Oeing, C. U., Nakamura, T., Pan, S., Mishra, S., Dunkerly-Eyring, B. L., Kokkonen-Simon, K. M., Lin, B. L., Chen, A., Zhu, G., Bedja, D., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315714 · Cited by 49
Sex and Gender Bias as a Mechanistic Determinant of Cardiovascular Disease Outcomes
Kim, I., Field, T. S., Wan, D., Humphries, K. H., & Sedlak, T. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.09.009 · Cited by 57
Functional and Symptomatic Clinical Trial Endpoints
Psotka, M. A., Abraham, W. T., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Ahmad, T., Felker, G. M., Jacob, R., Kitzman, D. W., Leifer, E., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.012 · Cited by 55
Self-citationMollace, R., Scarano, F., Bava, I., Carresi, C., Maiuolo, J., Tavernese, A., Gliozzi, M., Musolino, V., Muscoli, S., Palma, E., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106931 · Cited by 52
Butt, J. H., Docherty, K. F., Petrie, M. C., Schou, M., Kosiborod, M., O’Meara, E., Katova, T., Ljungman, C. E. A., Díez, M., Ogunniyi, M. O., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0379 · Cited by 61
Self-citationHulot, J., Trochu, J., Donal, E., Galinier, M., Logeart, D., de Groote, P., & Juillière, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1937121 · Cited by 54
Werbner, B., Tavakoli‐Rouzbehani, O. M., Fatahian, A. N., & Boudina, S. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.42 · Cited by 53
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Cooper, T. J., Cleland, J. G. F., Guazzi, M., Pellicori, P., Gal, T. B., Amir, O., Al‐Mohammad, A., Clark, A. L., McConnachie, A., Steine, K., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2527 · Cited by 49
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure
Alcidi, G., Goffredo, G., Correale, M., Brunetti, N. D., & Iacoviello, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113192 · Cited by 51
Consensus statement on the current pharmacological prevention and management of heart failure
Sindone, A. P., Pasquale, C. G. D., Amerena, J. V., Burdeniuk, C., Chan, A., Coats, A. J. S., Hare, D. L., Macdonald, P. S., Sverdlov, A. L., & Atherton, J. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51656 · Cited by 48
Oxidative Stress as a Therapeutic Target of Cardiac Remodeling
Martins, D., Garcia, L. R., Queiróz, D. A. R., Lazzarin, T., Tonon, C. R., Balin, P. D. S., Polegato, B. F., de Paiva, S. A. R., Azevedo, P. S., Minicucci, M. F., et al. (2022) · Antioxidants · doi:10.3390/antiox11122371 · Cited by 49
“The study showed that in patients treated with Vericiguat, the incidence of primary outcomes (heart failure hospitalizations or cardiovascular death) was lower than in patients treated with placebo [73].”
Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease
He, M., Wang, D., Xu, Y., Jiang, F., Zheng, J., Feng, Y., Cao, J.-M., & Zhou, X. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071345 · Cited by 52
“Vericiguat can be used to treat heart failure with reduced ejection fraction [75].”
BackgroundMethodSenni, M., Alemayehu, W. G., Sim, D., Edelmann, F., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., O’Connor, C. M., Pieske, B. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2608 · Cited by 54
Self-citationArrigo, M., Biegus, J., Asakage, A., Mebazaa, A., Davison, B. A., Edwards, C., Adamo, M., Barros, M., Čelutkienė, J., Čerlinskaitė‐Bajorė, K., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2920 · Cited by 45
Self-citationVaduganathan, M., Cunningham, J. W., Claggett, B. L., Causland, F. M., Barkoudah, E., Finn, P. V., Zannad, F. M., Pfeffer, M. A., Rizkala, A. R., Sabarwal, S. V., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.01.014 · Cited by 47
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines
Tsutsui, H. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108185 · Cited by 47
A Year in Heart Failure: An Update of Recent Findings
Stretti, L., Zippo, D., Coats, A. J. S., Anker, M. S., von Haehling, S., Metra, M., & Tomasoni, D. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13760 · Cited by 52
“nous diuretic therapy.(148) According to this trial, it may be”
BackgroundBlumer, V. L., Mentz, R. J., Sun, J., Butler, J., Metra, M., Voors, A. A., Hernandez, A. F., O’Connor, C. M., & Greene, S. J. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007871 · Cited by 51
Self-citationButler, J., Stebbins, A., Melenovský, V., Sweitzer, N. K., Cowie, M., Stehlik, J., Khan, M. S., Blaustein, R. O., Ezekowitz, J. A., Hernandez, A. F., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009337 · Cited by 44
Self-citationLavalle, C., Mariani, M. V., Severino, P., Palombi, M., Trivigno, S., D’Amato, A., Silvetti, G., Pierucci, N., Lullo, L. D., Chimenti, C., et al. (2024) · Cardiorenal Medicine · doi:10.1159/000541393 · Cited by 45
Rüdebusch, J., Benkner, A., Nath, N., Fleuch, L., Kaderali, L., Grube, K., Klingel, K., Eckstein, G., Meitinger, T., Fielitz, J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15333 · Cited by 43
Endocrine functions of the heart: from bench to bedside
Volpe, M., Gallo, G., & Rubattu, S. D. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac759 · Cited by 51
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
Reddy, Y. N. V., Butler, J., Anstrom, K. J., Blaustein, R. O., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., Lewis, E. F., Lindenfeld, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3501 · Cited by 52
Self-citationPacker, M., Januzzi, J. L., Ferreira, J. P., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2256 · Cited by 50
Self-citationWinkle, P. J., Goldsmith, S. R., Koren, M. J., Lepage, S., Hellawell, J. L., Trivedi, A., Tsirtsonis, K., Abbasi, S. A., Kaufman, A., Troughton, R. W., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07328-w · Cited by 40
Self-citationGreene, S. J., Tan, X., Yeh, Y., Bernauer, M. J., Zaidi, O., Yang, M., & Butler, J. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10077-x · Cited by 46
Self-citationVericiguat for Heart Failure with Reduced Ejection Fraction
Lombardi, C., Cimino, G., Pagnesi, M., Dell’Aquila, A., Tomasoni, D., Ravera, A., Inciardi, R. M., Carubelli, V., Vizzardi, E., Nodari, S., et al. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01580-6 · Cited by 47
Pieske, B. M., Pieske‐Kraigher, E., Lam, C. S. P., Melenovský, V., Sliwa, K. S., Lopatin, Y. M., Arango, J. L., Bahit, M. C., O’Connor, C. M., Patel, M. J., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2836 · Cited by 43
Self-citationComorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 65
Riociguat: Clinical research and evolving role in therapy
Klinger, J. R., Chakinala, M. M., Langleben, D., Rosenkranz, S., & Sitbon, O. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14676 · Cited by 40
“A recent study of the sGC stimulator vericiguat, however, showed a significant reduction in a composite endpoint of death from cardiovascular causes or first hospitalisation for heart failure compared with placebo in patients with heart failure with reduced ejection fraction.(56)”
BackgroundXu, L., Chen, L., Gu, G., Wang, Y., Xu, Y., & Zhong, Y.-G. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2302060 · Cited by 40
“Indeed, there are some novel drugs used to treat HF in clinical trials, such as vericiguat (an oral soluble guanylate cyclase stimulator) [5], finerenone (a third-generation mineralocorticoid receptor antagonist) [6,7] and ferric carboxymaltose [8], however, not all of them have an apparent effect…”
BackgroundXia, J., Hui, N., Tian, L., Liang, C., Zhang, J., Liu, J., Wang, J., Ren, X., Xie, X., & Wang, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112894 · Cited by 43
The economics of heart failure care
Chen, W., Heidenreich, P. A., & Sandhu, A. T. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.010 · Cited by 46
Rosano, G. M. C., Stolfo, D., Anderson, L., Abdelhamid, M., Adamo, M., Bauersachs, J., Bayés‐Genís, A., Böhm, M., Chioncel, O. D., Filippatos, G. S., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3284 · Cited by 50
Marino, F., Scalise, M., Cianflone, E., Salerno, L., Cappetta, D., Salerno, N., Angelis, A. D., Torella, D., & Urbanek, K. (2021) · Antioxidants · doi:10.3390/antiox10071002 · Cited by 42
Ortíz, A., Navarro‐González, J. F., Núñez, J. E., de la Espriella, R., Cobo, M., Santamaría, R., de Sequera, P., & Díez, J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab290 · Cited by 38
“Vericiguat in Participants with Heart Failure with Reduced Ejection Fraction trial [45].”
MethodMatsukawa, R., Okahara, A., Tokutome, M., Itonaga, J., Koga, E., Hara, A., Kisanuki, H., Sada, M., Okabe, K., Kawai, S., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14524 · Cited by 39
“22,23 Further analysis using a new scoring system with the addition of these two drugs will be necessary in the future.”
MethodCyclic nucleotide phosphodiesterases as drug targets
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Heßlinger, C., Nickolaus, P., Kass, D. A., de Vasconcelos, W. P., Fischmeister, R., Brocke, S., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100042 · Cited by 39
Li, H., Förstermann, U., Xia, N., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.06.009 · Cited by 41
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 40
“The latest results showed that the incidence of death from cardiovascular causes or HHF was lower among those who received vericiguat than among those who received placebo [193] .”
BackgroundTreatment of HF in an Era of Multiple Therapies
Bhatt, A. S., Abraham, W. T., Lindenfeld, J., Bristow, M. R., Carson, P. E., Felker, G. M., Fonarow, G. C., Greene, S. J., Psotka, M. A., Solomon, S. D., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.014 · Cited by 38
Self-citationSoluble guanylate cyclase stimulators and their potential use: a patent review
Sandner, P., Vakalopoulos, A., Hahn, M. G., Stasch, J., & Follmann, M. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1866538 · Cited by 41
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. K. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1061 · Cited by 44
“133 115 Armstrong et al. , 126 and Teerlink et al. 132 The year in CV Medicine: HF and cardiomyopathies On the other hand, mavacamten , a myosin inhibitor, significantly improved the combined primary endpoint of increase in peak oxygen consumption (pVO 2 ) and reduction in NYHA class in a phase 3…”
Richards, D. A., Aronovitz, M. J., Liu, P., Martin, G., Tam, K., Pande, S., Karas, R. H., Bloomfield, D. M., Mendelsohn, M. E., & Blanton, R. M. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007300 · Cited by 35
Pulmonary Hypertension in Left Heart Disease
Reddy, Y. N. V., & Borlaug, B. A. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.11.002 · Cited by 40
Metra, M., Pagnesi, M., Claggett, B. L., Díaz, R., Felker, G. M., McMurray, J. J. V., Solomon, S. D., Bonderman, D., Fang, J. C.-T., Fonseca, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac293 · Cited by 39
“43 In contrast, GALACTIC-HF included patients with SBP ≥ 85 mmHg, thus providing data on 1473 enrolled patients with SBP ≤ 100 mmHg.”
MethodCox, Z. L., Nandkeolyar, S., Johnson, A. J., Lindenfeld, J. M., & Rali, A. S. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.08 · Cited by 41
Endogenous Hemoprotein-Dependent Signaling Pathways of Nitric Oxide and Nitrite
Dent, M. R., DeMartino, A. W., Tejero, J., & Gladwin, M. T. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c01048 · Cited by 36
Sequential Evaluation of NT-proBNP in Heart Failure
Armstrong, P. W., Zheng, Y., Troughton, R. W., Lund, L. H., Zhang, J., Lam, C. S. P., Westerhout, C. M., Blaustein, R. O., Butler, J., Hernandez, A. F., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.04.015 · Cited by 35
Self-citationBenardeau, A. M., Kahnert, A., Schomber, T., Meyer, J., Pavkovic, M., Kretschmer, A., Lawrenz, B., Hartmann, E., Mathar, I., Hueser, J., et al. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02149-4 · Cited by 41
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction
Saldarriaga, C., Atar, D., Stebbins, A., Lewis, B. S., Abidin, I. Z., Blaustein, R. O., Butler, J., Ezekowitz, J. A., Hernandez, A. F., Lam, C. S. P., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2468 · Cited by 38
Self-citationAssessment and management of heart failure in patients with chronic kidney disease
Guaricci, A. I., Sturdà, F., Russo, R., Basile, P., Baggiano, A., Mushtaq, S., Fusini, L., Fazzari, F., Bertandino, F., Monitillo, F., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10346-x · Cited by 47
Heart failure with reduced ejection fraction
Cannata, A. N., Crespo-Leiro, M. G., Bromage, D. I., Ruschitzka, F., & McDonagh, T. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01851-3 · Cited by 44
Spertus, J. A., Birmingham, M. C., Butler, J., Lingvay, I., Lanfear, D. E., Abbate, A., Kosiborod, M., Fawcett, C., Burton, P. B. J., Damaraju, C. V., et al. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007767 · Cited by 38
Self-citationButler, J., Usman, M., Anstrom, K. J., Blaustein, R. O., Bonaca, M. P., Ezekowitz, J. A., Freitas, C., Lam, C. S. P., Lewis, E. F., Lindenfeld, J. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2720 · Cited by 34
“intravenous diuretic treatment within 3 months (10).”
BackgroundMethodInfluentialSelf-citationPharmacological modulation of vascular ageing: A review from VascAgeNet
Roth, L., Doğan, S., Tuna, B. G., Arányi, T., Benítez, S., Borrell-Pagés, M., Bozaykut, P., Meyer, G. R. Y. D., Duca, L., Durmuş, N., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102122 · Cited by 43
“There is ample evidence that these compounds increase cGMP and vasodilation, attenuate high blood pressure, and display a protective effect in patients with acute heart failure (Armstrong et al., 2020; Ataei Ataabadi et al., 2020).”
BackgroundBöettcher, M., Loewen, S., Gerrits, M., & Becker, C. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00935-6 · Cited by 34
Biology of myocardial recovery in advanced heart failure with long-term mechanical support
Tseliou, E., Lavine, K. J., Wever‐Pinzon, O., Topkara, V. K., Meyns, B. P., Adachi, I., Zimpfer, D., Birks, E. J., Burkhoff, D., & Drakos, S. G. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.007 · Cited by 38
Targeting estrogen receptor signaling for treating heart failure
Qian, C., Liu, J., & Liu, H. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10356-9 · Cited by 38
“…possible approach is to upregulate myocardial cGMP signaling, as examined in the Vericiguat Global trial in Subjects with Heart Failure and Reduced Ejection Fraction (VICTORIA), where it was found that the soluble guanylate cyclase (sGC) stimulant, vericiguat, exerted cardioprotective effects [49].”
BackgroundAdvances in management of heart failure
Heidenreich, P. A., & Sandhu, A. T. (2024) · BMJ · doi:10.1136/bmj-2023-077025 · Cited by 43
“72 However, patients in the highest quarter of natriuretic peptide concentrations were less likely to benefit from vericiguat compared with placebo.”
BackgroundTharp, C. A., Mestroni, L., & Taylor, M. R. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092770 · Cited by 35
“Compared to placebo, treatment with vericiguat reduced hospitalizations and cardiovascular death among patients with systolic dysfunction [91].”
ResultAlsumali, A., Djatche, L. M., Briggs, A. H., Liu, R., Diakite, I., Patel, D. A., Wang, Y., & Lautsch, D. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01091-w · Cited by 32
“Such differences were likely due to the fact that the VICTORIA population had recently experienced a WHFE [9] and therefore had worse prognoses and clinical outcomes.”
BackgroundMethodResultInfluentialMedical Therapy for Functional Mitral Regurgitation
Milwidsky, A., Mathai, S. V., Topilsky, Y., & Jorde, U. P. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009689 · Cited by 38
Gut barrier dysfunction and endotoxemia in heart failure: A dangerous connubium?
Violi, F., Castellani, V., Menichelli, D., Pignatelli, P., & Pastori, D. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.06.002 · Cited by 35
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.